Table 1.
Basic characteristics of enrolled patients.
| N | % | |
|---|---|---|
| Age, median, years (range) | 52 (28–81) | |
| Sex | ||
| Female | 50 | 100.0 |
| Staging (AJCC Seventh Edition) | ||
| Stage IV | 50 | 100.0 |
| Performance status (ECOG) | ||
| 0–1 | 43 | 86.0 |
| ⩾2 | 7 | 14.0 |
| Receptor status | ||
| ER and/or PR positive | 36 | 72.0 |
| HER-2/neu positive | 24 | 48.0 |
| Triple-negative (ER/PR/HER-2) | 8 | 16.0 |
| Number of metastases | ||
| Single metastasis | 17 | 34.0 |
| ⩾2 metastases | 33 | 66.0 |
| Site of distant metastasis at study enrollment | ||
| Visceral metastasis † | 36 | 72.0 |
| Nonvisceral metastasis | 14 | 28.0 |
†
Visceral sites include the lungs, liver, brain, adrenal glands, and pleura (with or without effusion). Nonvisceral sites were defined as the breast, lymph nodes, chest wall, bones, and skin.
AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; CI: confidence interval; ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2; OS: overall survival; PFS: progression-free survival; PR, progesterone receptor; SD: standard deviation.